Pelage Pharmaceutical

Pelage Pharmaceutical

Stimulating hair growth by targeting hair follicle stem cells, activating dormant cells in all forms of alopecia, and delivering a scientifically based, non-invasive, topical small molecule drug platform. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
AUD129m (Public information from Aug 2024)
Los Angeles California (HQ)
  • Edit
DateInvestorsAmountRound
*

$16.8m

Series A
*

$14.0m

Valuation: $83.8m

Series A
Total FundingAUD47.5m

Recent News about Pelage Pharmaceutical

Edit
More about Pelage Pharmaceuticalinfo icon
Edit

Pelage Pharmaceuticals is a pioneering biotech company focused on developing scientifically based treatments for hair loss. Operating in the pharmaceutical and biotechnology market, Pelage Pharmaceuticals aims to serve both men and women who suffer from the emotional and social impacts of hair loss. The company's core product is a novel drug that targets hair follicle stem cells, a groundbreaking approach based on discoveries from UCLA. Unlike existing therapies that address external factors, Pelage's solution activates the unique metabolism of hair follicle stem cells to stimulate hair growth. The business model revolves around the development, clinical testing, and eventual commercialization of this innovative treatment. Revenue is generated through the sale of the drug, once approved, to healthcare providers and directly to consumers.

Keywords: biotech, hair loss, stem cells, hair growth, pharmaceutical, clinical testing, innovative treatment, UCLA discovery, emotional impact, social stigma.